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PHARMACY NEWS
Pharmacy presentations on international plat-
form - Federation of International Pharmaceu-
tical 69th congress (Istanbul, Turkey)
This year, the 69th FIP international annual con-
gress held in stunning and historically rich city Is-
tanbul, Turkey from September 2009. The theme
of this year’s congress was Responsibility for Pa-
tient Outcomes – Are You Ready? Around 5000
pharmacists from different parts of the world at-
tended this year’s congress. The congress of-
fered many scientific and plenary sessions where
pharmacists shared their research, practices, in-
novations and local experiences in the area of
their expertise. It was a platform to teach and
learn reciprocally and exchange the ideas for the
amelioration of the profession across the globe. 
A total of 11 abstracts were accepted this year in
the FIP congress from Department of Pharmacy
Services, AKUH. Four abstracts’ authors were
chosen to present their research work on the
podium as oral presentations and seven abstracts
were presented as posters. Department of Phar-
macy AKUH as well as Pakistan were repre-
sented by three participants, Mr Abdul Latif
Sheikh (Pharmacy Consultant AKUH), Mr Syed
Shamim Raza (Manager Pharmacy Services
AKUH) and Mr Muhammad Hammad (Clinical
Pharmacist AKUH). 
Hospital Pharmacy Practice Symposium
A symposium was organised by the Society of
Hospital Pharmacist’s of Pakistan (SHPP) in col-
laboration with Riphah Institute of Pharmaceutical
Sciences in which the current role of the pharma-
cist in hospital pharmacy and future prospects
were presented by AKUH’s pharmacy staff. In the
symposium in addition to career counseling,
awareness of hospital pharmacy practice and its
scope in Pakistan were highlighted, The sympo-
sium included the presentation and interactive
sessions from the expert professionals in hospi-
tal pharmacy practice covering all the speciality
including drug distribution systems, pharmaceu-
tical care concepts, specialised services, phar-
macy practice research and role of the
pharmacist in an effective medication manage-
ment system. The following presentation topics
were presented Future of Hospital Pharmacy:
Global Perspective and Basel Statement
Overview by Mr Abdul Latif Sheikh, President,
SHPP Consultant, Pharmacy Services, AKUH;
Pharmacist’s role in Medication Management
System by Ms Salwa Zubair, Assistant Manager,
Department of Pharmacy Services, AKUH.
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Propylthiouracil
Stimulant medications used in 
children with attention-deficit/
hyperactivity disorder - 
communication about an ongoing 
safety review
Cefepime update of 
ongoing safety review
Immunosuppressant drugs: 
required labeling changes
Varenicline and bupropion 
(risk of serious neuropsychiatric 
symptoms)
Leukotriene inhibitors
Mycophenolate mofetil (Cellcept)
Promethazine hydrochloride 
injection and severe tissue injury
FDA notified healthcare professionals of the risk of serious liver
injury, including liver failure and death, with the use of propylth-
iouracil in adult and paediatric patients. Physicians should
closely monitor patients on propylthiouracil therapy for symp-
toms and signs of liver injury, especially during the first six
months after initiation of therapy.
Potential risks of stimulant medications used to treat Attention-
Deficit/Hyperactivity Disorder (ADHD) in children. There may be
an association between the use of stimulant medications and
sudden death in healthy children. The FDA is unable to conclude
that these data affect the overall risk and benefit profile of stimu-
lant medications used to treat ADHD in children. FDA believes
that this study should not serve as a basis for parents to stop a
child’s stimulant medication. Any child who develops cardiovas-
cular symptoms (such as chest pain, shortness of breath or
fainting) during stimulant medication treatment should immedi-
ately be seen by a doctor.  
Possible higher risk of death with cefepime, an antibiotic. FDA
has determined that the data do not indicate a higher rate of
death in cefepime-treated patients. Cefepime remains an appro-
priate therapy for its approved indications.
Certain immunosuppressant drugs to update their labeling to re-
flect that immunosuppressed patients are at increased risk for
opportunistic infections, such as activation of latent viral infec-
tions, including BK virus-associated nephropathy.
FDA notified healthcare professionals and patients that it has re-
quired the manufacturers of the smoking cessation aids vareni-
cline and bupropion  to add new Boxed Warnings and develop
patient Medication Guides highlighting the risk of serious neu-
ropsychiatric symptoms in patients using these products. These
symptoms include changes in behaviour, hostility, agitation, de-
pressed mood, suicidal thoughts and behaviour, and attempted
suicide. The added warnings are based on the continued review
of postmarketing adverse event reports for varenicline and
bupropion received by the FDA. These reports included those
with a temporal relationship between the use of varenicline or
bupropion and suicidal events and the occurrence of suicidal
ideation and suicidal behaviour in patients with no history of psy-
chiatric disease.
FDA has requested that manufacturers of Leukotriene Inhibitors
(Monteleukast and others) include a precaution in the drug pre-
scribing information (drug labeling) about the neuropsychiatric
events include postmarket cases of agitation, aggression, anx-
iousness, dream abnormalities and hallucinations, depression,
insomnia, irritability, restlessness, suicidal thinking and behav-
iour (including suicide), and tremor. FDA recommends that:
• Patients and healthcare professionals should be aware of the 
potential for neuropsychiatric events with these medications.
• Patients should talk with their healthcare providers if these     
events occur.
• Healthcare professionals should consider discontinuing these 
medications if patients develop neuropsychiatric symptoms.
FDA notified that cases of Pure Red Cell Aplasia (PRCA) have
been reported in patients treated with Mycophenolate. The
WARNINGS and ADVERSE REACTIONS sections of the My-
cophenolate Prescribing Information have been revised to reflect
this new safety information. PRCA is a type of anaemia in which
there is a selective reduction of red blood cell precursors on
bone marrow examination. Patients with PRCA may present with
fatigue, lethargy, and/or abnormal paleness of the skin (pallor).
In some cases, PRCA was found to be reversible with dose re-
duction or cessation of therapy. In transplant patients, however,
reduced immunosuppression may place the graft at risk.
A Boxed Warning is being added to the prescribing information
for Promethazine Hydrochloride products, describing the risks of
severe tissue injury, including gangrene, requiring amputation
following intravenous administration of promethazine. The
Boxed Warning will remind practitioners that due to the risks of
intravenous injection, the preferred route of administration is
deep intramuscular injection and that subcutaneous injection is
contraindicated.
Summary of FDA Alerts 2009
Month Drug(s) Summary
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DRUG SAFETY UPDATE
Ceftriaxone interaction with calcium
FDA notified healthcare professionals of an
update to a previous alert that addresses the
interaction of ceftriaxone with calcium-con-
taining products, based on previously re-
ported fatal cases in neonates. Two in-vitro
studies were conducted to assess the poten-
tial for precipitation of ceftriaxone-calcium
when ceftriaxone and calcium-containing
products are mixed in vials and in infusion
lines. These two in vitro studies were con-
ducted in neonatal and adult plasma to as-
sess the potential for precipitation of
ceftriaxone-calcium using varying ceftriaxone
and calcium concentrations, including con-
centrations in excess of those achieved in-
vivo. Based on the results of these studies,
FDA now recommends that ceftriaxone and
calcium-containing products may be used
concomitantly in patients older than 28 days
of age, using the precautionary recommenda-
tions noted because the risk of precipitation is
low in this population. FDA had previously
recommended, but no longer recommends,
that in all age groups ceftriaxone and cal-
cium-containing products should not be ad-
ministered within 48 hours of one another. 
SWINE FLU UPDATE
In late March and early April 2009, an out-
break of H1N1 influenza A virus infection was
detected in Mexico, with subsequent cases
observed in many other countries including
the United State. On June 11, 2009, the
World Health Organization raised its pan-
demic alert level to the highest level, phase 6,
indicating widespread community transmis-
sion on at least two continents. Two classes
of antiviral drugs are available for the treat-
ment and prevention of influenza : the neu-
raminidase inhibitors zanamivir and
oseltamivir, which are active against both in-
fluenza A and B. The adamantanes, amanta-
dine and rimantadine, which are only active
against influenza A. The first preparations for
pandemic H1N1 influenza vaccine became
available in the United States in early October
2009, though it will take time for adequate
supplies to be produced and distributed.
(Afsheen Zafar and Saba Saleem, Trainee
Pharmacists)
Acetaminophen after-shots may undermine
immune response in infants
According to a study published in the British
Medical Journal,The Lancet (2009), adminis-
tration of acetaminophen after vaccines re-
duces their efficacy and also that of
subsequent booster doses. An RCT was con-
ducted which included 459 healthy infants
and the research concluded that the effect of
acetaminophen has something to do with the
anti-inflammatory property of the drug; it inter-
rupts the “early innate and adaptive re-
sponses” to the vaccine shots. It is still okay
to use acetaminophen to treat fever, but just
not recommended to prevent it. (Fasiha Ab-
dulaziz, Trainee Pharmacist) 
EUROPEAN MIGRAINE GUIDELINES     
UPDATES
Zolmitriptan tablets and nasal spray and rizatrip-
tan tablets were determined to be effective in chil-
dren and adolescents.Topiramate is
recommended for prophylactic treatment of
chronic migraine. Botulinum toxin A is not consid-
ered effective in episodic migraine. For very se-
vere migraine attacks, the guidelines recommend
intravenous acetylsalicylic acid or subcutaneous
sumatriptan as the drugs of first choice. Status
migrainosus, in which migraine lasts almost with-
out interruption for more than 72 hours, "can be
treated by corticosteroids, although this is not uni-
versally held to be helpful, or dihydroergotamine,"
according to the recommendations. For migraine
prophylaxis, beta-blockers (propranolol and meto-
prolol), flunarizine, valproic acid, and topiramate
are the drugs of first choice.The guidelines also
include recommendations for specific situations,
such as emergencies, menstrual migraines, mi-
graine in pregnancy, and migraine in children and
adolescents.
